» Articles » PMID: 35925406

SORG Algorithm to Predict 3- and 12-month Survival in Metastatic Spinal Disease: a Cross-sectional Population-based Retrospective Study

Overview
Specialty Neurosurgery
Date 2022 Aug 4
PMID 35925406
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: In this study, we wished to compare statistically the novel SORG algorithm in predicting survival in spine metastatic disease versus currently used methods.

Methods: We recruited 40 patients with spinal metastatic disease who were operated at Geneva University Hospitals by the Neurosurgery or Orthopedic teams between the years of 2015 and 2020. We did an ROC analysis in order to determine the accuracy of the SORG ML algorithm and nomogram versus the Tokuhashi original and revised scores.

Results: The analysis of data of our independent cohort shows a clear advantage in terms of predictive ability of the SORG ML algorithm and nomogram in comparison with the Tokuhashi scores. The SORG ML had an AUC of 0.87 for 90 days and 0.85 for 1 year. The SORG nomogram showed a predictive ability at 90 days and 1 year with AUCs of 0.87 and 0.76 respectively. These results showed excellent discriminative ability as compared with the Tokuhashi original score which achieved AUCs of 0.70 and 0.69 and the Tokuhashi revised score which had AUCs of 0.65 and 0.71 for 3 months and 1 year respectively.

Conclusion: The predictive ability of the SORG ML algorithm and nomogram was superior to currently used preoperative survival estimation scores for spinal metastatic disease.

Citing Articles

Multidisciplinary Approach to Spinal Metastases and Metastatic Spinal Cord Compression-A New Integrative Flowchart for Patient Management.

Esperanca-Martins M, Roque D, Barroso T, Abrunhosa-Branquinho A, Belo D, Simas N Cancers (Basel). 2023; 15(6).

PMID: 36980681 PMC: 10046378. DOI: 10.3390/cancers15061796.

References
1.
Ahmed A, Goodwin C, Heravi A, Kim R, Abu-Bonsrah N, Sankey E . Predicting survival for metastatic spine disease: a comparison of nine scoring systems. Spine J. 2018; 18(10):1804-1814. DOI: 10.1016/j.spinee.2018.03.011. View

2.
Bollen L, van der Linden Y, Pondaag W, Fiocco M, Pattynama B, Marijnen C . Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1,043 patients. Neuro Oncol. 2014; 16(7):991-8. PMC: 4057139. DOI: 10.1093/neuonc/not318. View

3.
Groot O, Hundersmarck D, Lans A, Bongers M, Karhade A, Zhang Y . Postoperative adverse events secondary to iatrogenic vascular injury during anterior lumbar spinal surgery. Spine J. 2020; 21(5):795-802. DOI: 10.1016/j.spinee.2020.10.031. View

4.
Bouthors C, Prost S, Court C, Blondel B, Charles Y, Fuentes S . Outcomes of surgical treatments of spinal metastases: a prospective study. Support Care Cancer. 2019; 28(5):2127-2135. DOI: 10.1007/s00520-019-05015-5. View

5.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View